UK +44 (0)1865 849841
Malaysia +60 3 2117 5193
  • The Big List of Microfluidics Companies & Investors

    The microfluidic-based devices market has been growing since 2014 due to the increasing point of care testing demand and the miniaturisation of microfluidic chips. 

  • Precision Medicine & Companion Diagnostics

    A strokes presentation and clinical workup present unique challenges that can be addressed by a personalised medicine strategy where up to 40% of patients never have a cause determined, which are diagnosed as “cryptogenic”.

  • What will we do with all this Data?

    The amount of data we are creating every day has increased exponentially to match the rise in use of smart and connected devices. 

  • 119 AgTech Companies & Investors

    Whether you’re looking for an investor from seed to series or you’re just interested in the market, you are sure to find this resource useful.

  • Using Machine Learning to Assign Gene Ontology

    It is a quite common phenomenon in biology: we have identified a gene or a set of genes that are likely to be important for the system we are studying, but we have no clear explanation for why they are important or how they influence the system.

Continuous or intensified bioprocessing? The gold standard for improved productivity

Process intensification and continuous biomanufacturing continue to attract a lot of interest within the biopharmaceutical industry as a method that can increase productivity and make the most efficient use of production assets.

Read More

The Global NASH Congress – Slide release

An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.

Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.

Read More

Effective Implementation & Utilisation of Diagnostic Technology in the NHS

An inquiry by the House of Lords’ Science & Technology Committee has identified several issues that could hamper the delivery of the Life Sciences Industrial Strategy vision1. The critical report (Life Sciences Industrial Strategy: Who’s driving the bus? 1) brings together evidence from industry, academia and the NHS. It highlights several implementation challenges which require “prompt and vigorous action by the government” to ensure that the scope of Life Sciences Industrial Strategy can be achieved.

Read More

Why NOW for Targeting RNA with Small Molecules?

Before tackling the question of why everyone thinks drugging RNA is so hard, one might ask why drugging proteins is considered to be so easy (at least by comparison). Put differently, why were proteins first?

Read More

NIZO – A Case Study: helping you create microbiome modulators

Companies typically approach contract research companies with the aim to better understand single organisms, groups of organisms, metabolic pathways and the interaction with the host that make up the microbiome. In addition, companies search for compounds or modulators that could improve in the end the healthy state of the host. Such modulators could be prebiotics, probiotics, enzyme inhibitors, antimicrobials and more.

NIZO is an independent contract research company that works on proteins, bacteria and processing on behalf of their global client base in food and pharma. Their unique business model centres around performing industrially relevant research projects for the industry under strict confidentiality and with clear IP clauses.

Read More

Connecting Cancer Biology to Clinical Oncology: Still a World to Win

Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.

Read More

Using Machine Learning to Assign Gene Ontology

It is a quite common phenomenon in biology: we have identified a gene or a set of genes that are likely to be important for the system we are studying, but we have no clear explanation for why they are important or how they influence the system. For example, in plant genomics, we are often interested in a specific trait and have a genomic locus or a list of candidate genes that might affect this trait. The question is: how can we prioritise these genes in order to proceed to experimental validation?

To this end, it would be extremely useful if we knew the functions of our candidate genes. For instance, if a gene codes for an enzyme, what type of reaction does this enzyme catalyse? And in which pathways might this reaction take place?

Read More

What are the main bottlenecks for realising continuous manufacturing?

Bioprocesses are traditionally performed in (fed-) batch processes for the production of various recombinant proteins and therapeutics. Batch processing comprises of processes where the material flow has hold steps in between two unit operations where the product is recovered from each unit operation step. However, such batch processes are attributed to longer process time and costs, and inconsistent process performance.

Read More

Continuous or intensified bioprocessing? The gold standard for improved productivity

Process intensification and continuous biomanufacturing continue to attract a lot of interest within the biopharmaceutical industry as a method that can increase productivity and make the most efficient use of production assets.

Read More

The Global NASH Congress – Slide release

An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.

Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.

Read More

Effective Implementation & Utilisation of Diagnostic Technology in the NHS

An inquiry by the House of Lords’ Science & Technology Committee has identified several issues that could hamper the delivery of the Life Sciences Industrial Strategy vision1. The critical report (Life Sciences Industrial Strategy: Who’s driving the bus? 1) brings together evidence from industry, academia and the NHS. It highlights several implementation challenges which require “prompt and vigorous action by the government” to ensure that the scope of Life Sciences Industrial Strategy can be achieved.

Read More

Why NOW for Targeting RNA with Small Molecules?

Before tackling the question of why everyone thinks drugging RNA is so hard, one might ask why drugging proteins is considered to be so easy (at least by comparison). Put differently, why were proteins first?

Read More

NIZO – A Case Study: helping you create microbiome modulators

Companies typically approach contract research companies with the aim to better understand single organisms, groups of organisms, metabolic pathways and the interaction with the host that make up the microbiome. In addition, companies search for compounds or modulators that could improve in the end the healthy state of the host. Such modulators could be prebiotics, probiotics, enzyme inhibitors, antimicrobials and more.

NIZO is an independent contract research company that works on proteins, bacteria and processing on behalf of their global client base in food and pharma. Their unique business model centres around performing industrially relevant research projects for the industry under strict confidentiality and with clear IP clauses.

Read More

Connecting Cancer Biology to Clinical Oncology: Still a World to Win

Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.

Read More

What are the main bottlenecks for realising continuous manufacturing?

Bioprocesses are traditionally performed in (fed-) batch processes for the production of various recombinant proteins and therapeutics. Batch processing comprises of processes where the material flow has hold steps in between two unit operations where the product is recovered from each unit operation step. However, such batch processes are attributed to longer process time and costs, and inconsistent process performance.

Read More

Charting a Translational Roadmap in the Microbiome Space – A Multidimensional Challenge

The opportunity afforded by the microbiome for developing therapeutic and wellness products is matched only by the formidable task of unraveling the science of the microbiome in the first place. Microbiome research is transitioning from a descriptive to a more mechanistic science, and progress in understanding mechanisms that underpin microbiome biology is likely to result in a surge of interest in this space on the part of the biotech, pharma and investor communities.

Read More

Using Machine Learning to Assign Gene Ontology

It is a quite common phenomenon in biology: we have identified a gene or a set of genes that are likely to be important for the system we are studying, but we have no clear explanation for why they are important or how they influence the system. For example, in plant genomics, we are often interested in a specific trait and have a genomic locus or a list of candidate genes that might affect this trait. The question is: how can we prioritise these genes in order to proceed to experimental validation?

To this end, it would be extremely useful if we knew the functions of our candidate genes. For instance, if a gene codes for an enzyme, what type of reaction does this enzyme catalyse? And in which pathways might this reaction take place?

Read More

Bringing your Biopesticides to Market

The application of crop biotechnology in agriculture has permitted an enhanced level of income to farmers and environmental benefits, while also reducing cropland expansion. Insect-protected crops, such as corn, showed more than 10% increase in yield worldwide and insect-protected corn and cotton augmented farm income by >$56 billion between 1996 and 2001.

There are important factors to consider to ensure the value and the benefits of these products. These relate to their mode of delivery from suppliers to end users, including correct shipping, storage as well as user education.

Read More

To regulate or not to regulate: Current legal status for gene-edited crops

Gene editing is the latest and sexiest DNA editing tool in the continuum of plant breeding innovations. With genetically modified organism (GMO) technology, scientists introduce “foreign” genes, i.e. genes from a different organism, into crops. With gene editing, scientists create additional genetic variation by making precise changes to the existing crop’s genome. It offers great opportunities, but also creates regulatory challenges.

Read More

The Second Green Revolution: An Open Letter from Donald R. Marvin

Dear Colleagues,

Our vision of the Second Green Revolution goes beyond genetics, synthetic fertilizers, and chemical controls. It is a more holistic approach that integrates biologicals to optimize agriculture in a way that balances the immediate need for high yields and the long-term considerations for soil health.

Read More

119 Top AgTech Companies & Investors

2017 was a big year for the AgTech industry, with a record $10.1 billion in investments and an increase of 29% from 2016. Looking forward, we decided to put together a list of 119 top AgTech start-ups and investors.

In this article, we’ll be talking through the results that were gathered from the report, which you can view here.

Whether you’re looking for an investor from seed to series or you’re just interested in the market, you are sure to find this resource useful.

Read More

Round-Up of Top Plant Science News

It’s been a busy month in the field of Plant Science, with new discoveries, technologies, and research making the news. As the month draws to a close, we thought we’d reflect on the top stories.

This month, there was new insights into autophagy, previously extinct plant species, and the way in which climate change poses a potential threat to half of plant and animal species.

Take a look at the list below to find out more: 

Read More

Exploring the Orphan Crop: Pearl Millet

As an awardee of Global Engage’s Early Career Research grant, we are pleased to announce that Ambika Dudhate will be presenting her research about the drought tolerance in pearl millet in detail at the 6th Plant Genomics and Gene Editing Congress: Europe. It will be a great opportunity to discuss the topic on a large platform.

Read More

Is Palm Oil Sustainable for People?

Palm oil belongs to Elaeis, which is the only genus of Arecaceae family that produces edible oil. The current commercial planting is mainly E. guineensis, (Jacq.) originating from West Africa, selected due to its yield superiority. The cultivations occur throughout the tropical belt, especially in Southeast Asia, Africa and South America. To date, palm oil has become the most important oil crop in the world, accounting for 37% of global vegetable oil production. However, palm oil sustainability is always debated. Is palm oil really sustainable for people? To answer this, some facts are worth pondering.

Read More

When Blockchain Meets the Right to be Forgotten: Technology Versus Law

Over the past few years, the popularity of the blockchain and cryptocurrencies has increased and has reached important notoriety, not only in scientific and IT journals, but also in the media. Although there are many kinds of cryptocurrencies in circulation nowadays, the most popular is Bitcoin.

Read More

Supporting Blockchain Startups: An Open Letter from Katherine Merton

Dear colleagues,

The blockchain technology market is expected to grow to 2.3 billion US dollars by 2021, from 339.5 million US dollars in 2017. [1] With an annual growth rate of 61.5%, it is one of the fastest growing technologies in the healthcare industry.

Read More

The Big List of Microfluidics Companies & Investors

The microfluidic-based devices market has been growing since 2014 due to the increasing point of care testing demand and the miniaturisation of microfluidic chips. 

Read More

What will we do with all this data?

The amount of data we are creating every day has increased exponentially to match the rise in use of smart and connected devices. The internet of things has connected every aspect of our lives to the digital realm: most of these devices operate by tracking your habits, movements, preferences, voice, and more, then logging those habits online. Specifically, the collection of health data has become abundant, because most people now have or wear some sort of device to track daily patterns, steps, cycles, and more. Even our phones often default to track these things for us, whether we choose to enable the function or not.

Read More

How Standards & Standardised Infrastructure Fuel Innovation

It might surprise a lot of people to learn that standards can be viewed as a tool to support innovation, to set businesses free and to focus on the core of their product where their expertise lie. When working with the use of electronic communication systems within the entire healthcare sector, the main focal point is often ensuring a good support for collaboration and work processes.

Read More

The Development and Commercialisation of Robust Circulating DNA & RNA Tests

Precision medicine in oncology requires matching each patient with treatment personalised to their genes and often the proteomic profile of their cancer. Liquid biopsies continue to gain grounds as a tool for diagnostic testing in oncology.

Read More

The Coming Marriage Between Open Pharma Research and Blockchain

The pharmaceutical research industry is suffering from a lack of innovation, yet we see an exponential increase in new science and technologies. Open innovation, in the truest meaning, is a disruptive model that will greatly increase our joint chances of translating new research into treatments, but we need new ways of sharing and participating in collaborative drug research. Blockchain technologies can provide the digital infrastructure that allows trusted and secure transactions of research assets. Applying smart contracts on top of such infrastructure will further increase the speed of the life science ecosystem allowing exploration, co-creation, and transaction of research assets to happen in an unprecedented manner. In fact, we can’t afford to object to such a marriage between pharma open innovation and blockchain technologies.

Read More

Cyber Crime In The Digital Age

When I joined my first corporate IT-security department two decades ago (Electronic Data Processing Safety Department), I was presented with a memo between the department and the CEO.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive